




KNIGHT THERAPEUTICS UPDATE

Sector: Health Care – Biotechnology

(GUD-T: \$9.54; Dividend: \$0.00; Yield: 0.00%; Weekly Chart from March 2014)



In our previous publication (June 6, 2016 - \$8.61), we suggested that Knight Therapeutics was starting a new up-move. Following our report, the stock rallied to a high of \$9.82 for a 14% appreciation in three months (A).

The stock is currently somewhat extended and could have a minor correction toward \$8.50-9.00, but only a decline below \$8.00 would be negative.

Behaviour indicators including the 40wMA and the rising trend-line (solid line) confirm the bullish status.

Point & Figure measurements provide targets of \$10.50 and \$11.50 (10% and 21% appreciation potentials from current levels).

**Monica Rizk
Ron Meisels**

PAC-16-221; GUD-2; September 28, 2016

Phases & Cycles Inc, 2020 Robert-Bourassa, Suite 1903, Montreal, QC H3A 2A5

Tel.: (514) 393-3653 E-mail: RonMeisels@phases-cycles.com www.phases-cycles.com

The contents of this report may NOT be copied, reproduced, or distributed without the explicit written consent of Phases & Cycles Inc.

© Copyright 2016, Phases & Cycles Inc. All Rights Reserved

The opinions and projections contained herein are those of Phases & Cycles Inc., its principals, associates and employees (collectively "the researchers") and are subject to change without notice. The information contained herein has been obtained from sources that we believe to be reliable but cannot guarantee its accuracy or completeness. This report is not and under no circumstances is to be construed as an offer to sell or the solicitation of an offer to buy any securities. This report is furnished on the basis and understanding that "the researchers" are to be under no responsibility or liability whatsoever in respect thereof. "The researchers" may, from time to time, buy, own or sell securities mentioned herein. "Phases & Cycles" is a registered trademark of 104443 Canada Inc.